| 1 |
34196110 | Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. | 2022 Apr |
1 |
| 2 |
33751406 | Pemafibrate, a novel selective PPARĪ± modulator, attenuates tamoxifen-induced fatty liver disease. | 2021 Jun |
3 |
| 3 |
34265069 | Hormonally Regulated Myogenic miR-486 Influences Sex-specific Differences in Cancer-induced Skeletal Muscle Defects. | 2021 Oct 1 |
2 |
| 4 |
22915089 | Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. | 2013 Mar 15 |
3 |
| 5 |
19967559 | Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. | 2010 Oct |
3 |
| 6 |
21224536 | [The combined effect of Paclitaxel and toremifene therapy for estrogen receptor positive and aromatase inhibitor resistant metastatic breast cancer]. | 2010 Nov |
2 |
| 7 |
19013008 | The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. | 2009 Mar |
2 |
| 8 |
19468285 | Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells. | 2009 |
1 |
| 9 |
16474548 | Therapy Insight: osteoporosis during hormone therapy for prostate cancer. | 2005 Dec |
1 |
| 10 |
14719069 | Primary toremifene treatment for elderly postmenopausal women with breast cancer. | 2004 Feb |
2 |
| 11 |
12870885 | Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. | 2003 Jul |
1 |
| 12 |
11032589 | Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. | 2000 Oct 15 |
2 |
| 13 |
10573106 | Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. | 1999 Jul |
4 |
| 14 |
9556785 | Phase II and III clinical trials of toremifene for metastatic breast cancer. | 1998 Mar |
4 |
| 15 |
9716605 | Anti-estrogens induce apoptosis of multiple myeloma cells. | 1998 Sep 1 |
2 |
| 16 |
21223440 | New antiestrogens in breast cancer: a review. | 1998 Jul |
1 |
| 17 |
9165502 | Phase I and II studies of toremifene. | 1997 May |
3 |
| 18 |
9165504 | High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. | 1997 May |
1 |
| 19 |
9279356 | [Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. | 1997 Aug |
1 |
| 20 |
9448099 | Anti-proliferative effect of toremifene and tamoxifen on estrogen receptor-lacking anaplastic thyroid carcinoma cell lines. | 1997 Dec |
1 |
| 21 |
7553677 | Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines. | 1995 |
1 |
| 22 |
7579504 | High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB). | 1995 |
3 |
| 23 |
2143180 | In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay. | 1990 May |
2 |